Skip to main content Accessibility help
×
Home

N-Methyl-d-aspartate receptors and glutamate neurotransmission: an overview in pathological conditions and treatment

  • David R. Spiegel (a1)
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      N-Methyl-d-aspartate receptors and glutamate neurotransmission: an overview in pathological conditions and treatment
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      N-Methyl-d-aspartate receptors and glutamate neurotransmission: an overview in pathological conditions and treatment
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      N-Methyl-d-aspartate receptors and glutamate neurotransmission: an overview in pathological conditions and treatment
      Available formats
      ×

Abstract

Copyright

References

Hide All
1.Meldrum, BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr 2000;130(4S Suppl):1007S1015S.
2.Oliet, SH, Mothet, JP. Regulation of N-methyl-d-aspartate receptors by astrocytic d-serine. Neuroscience 2009;158:275283.
3.Chen, HS, Lipton, SA. The chemical biology of clinically tolerated NMDA receptor antagonists. J Neurochem 2006;97:16111626.
4.Goff, DC, Coyle, JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 2001;158:13671377.
5.Essa, MM, Braidy, N, Vijayan, KRet al. Excitotoxicity in the pathogenesis of autism. Neurotox Res 2013;23:393400.
6.Gandal, MJ, Anderson, RL, Billingslea, ENet al. Mice with reduced NMDA receptor expression: more consistent with autism than schizophrenia? Genes Brain Behav 2012;11:740750.
7.Kalia, LV, Kalia, SK, Salter, MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol 2008;7:742755.
8.Walther, S, Koschorke, P, Horn, Het al. Objectively measured motor activity in schizophrenia challenges the validity of expert ratings. Psychiatry Res 2009;169:187190.
9.Andreasen, NC. The evolving concept of schizophrenia: from Kraepelin to the present and future. Schizophr Res 1997;28:105109.
10.Berle, JO, Hauge, ER, Oedegaard, KJet al. Actigraphic registration of motor activity reveals a more structured behavioural pattern in schizophrenia than in major depression. BMC Res Notes 2010;3:149.
11.Homayoun, H, Stefani, MR, Adams, BWet al. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 2004;29:12591269.
12.Heresco-Levy, U. Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia. Expert Opin Emerg Drugs 2005;10:827844.
13.Surges, R, Volynski, KE, Walker, MC. Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited. Ther Adv Neurol Disord 2008;1:1324.
14.Tariot, PN, Farlow, MR, Grossberg, GTet al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317324.
15.Zoccolella, S, Santamato, A, Lamberti, P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat 2009;5:577595.
16.Yahn, SL, Watterson, LR, Olive, MF. Safety and efficacy of acamprosate for the treatment of alcohol dependence. Subst Abuse 2013;6:112.
17.Deutsch, SI, Pepe, GJ, Burket, JA et al. D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Brain Res 2012;1439:96–107.
18.Dean, O, Giorlando, F, Berk, M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 2011;36:7886.

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed